divarasib

Divarasib (GDC-6036) (GDC-6036)是一种正在研究的、口服的、高效力和选择性的 KRAS G12C 抑制剂，IC50 为 <0.01 μM。Divarasib 不可逆地将 KRAS G12C 癌蛋白锁定在非活性状态，抑制肿瘤细胞生长。它正在被研究用于实体肿瘤，包括非小细胞肺癌和结肠直肠癌及其他类型的癌症。

Divarasib (GDC-6036) adipate is a selective and highly potent KRAS G12C inhibitor with an impressively low IC 50 value of <0.01 μM, designed for oral administration. It covalently attaches to the switch II (SW-II) pocket in KRAS G12C, irreversibly maintaining the protein in its inactive GDP-bound state [1] [2].